Gross Margin % is calculated as gross profit divided by its revenue. Entera Bio's Gross Profit for the
three
months ended in Sep. 2024 was $0.00 Mil. Entera Bio's Revenue for the
three
months ended in Sep. 2024 was $0.04 Mil. Therefore, Entera Bio's Gross Margin % for the quarter that ended in Sep. 2024 was 0.00%.
The historical rank and industry rank for Entera Bio's Gross Margin % or its related term are showing as below:
ENTX'
s Gross Margin % Range Over the Past 10 Years
Min: 9.09 Med: 21.22 Max: 34.68
Current: 9.09
During the past 9 years, the highestGross Margin % of Entera Bio was 34.68%. The lowest was 9.09%. And the median was 21.22%.
ENTX's Gross Margin % is ranked worse than 89.23% of 743
companies
in the Biotechnology industry
Industry Median: 60.3
vs ENTX: 9.09
Entera Bio had a gross margin of 0.00% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Entera Bio was 0.00% per year.
Entera Bio Gross Margin % Historical Data
The historical data trend for Entera Bio's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Entera Bio's Gross Margin %
For the Biotechnology subindustry, Entera Bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entera Bio's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entera Bio's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Entera Bio's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Entera Bio (NAS:ENTX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Entera Bio had a gross margin of 0.00% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Entera Bio Gross Margin % Related Terms
Thank you for viewing the detailed overview of Entera Bio's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENTX has been successfully added to your 